Philip K-T Li

List of Publications by Year
in descending order

181 papers	7,511 citations	61857 43 h-index	58464 82 g-index
190 all docs	190 docs citations	190 times ranked	5093 citing authors

#	Article	IF	Citations
1	Predictors and prognostic significance of persistent fluid overload: A longitudinal study in Chinese peritoneal dialysis patients. Peritoneal Dialysis International, 2023, 43, 252-262.	1.1	4
2	Adipose expression of miR-130b and miR-17-5p with wasting, cardiovascular event and mortality in advanced chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 1935-1943.	0.4	8
3	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. Patient Education and Counseling, 2022, 105, 243-245.	1.0	2
4	Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Peritoneal Dialysis International, 2022, 42, 162-170.	1.1	4
5	Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium â€“ A single centre experience spanning 20 years. Peritoneal Dialysis International, 2022, 42, 204-211.	1.1	5
6	Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. Peritoneal Dialysis International, 2022, 42, 8-24.	1.1	33
7	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	3.0	10
8	Stability and compatibility of antibiotics in peritoneal dialysis solutions. CKJ: Clinical Kidney Journal, 2022, 15, 1071-1078.	1.4	7
9	Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nature Reviews Nephrology, 2022, 18, 185-198.	4.1	60
10	Recent advances in novel diagnostic testing for peritoneal dialysis-related peritonitis. Kidney Research and Clinical Practice, 2022, , .	0.9	5
11	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 2022, 42, 110-153.	1.1	209
12	The Clinical Utility of the Neutrophil-to-Lymphocyte Ratio as a Discriminatory Test among Bacterial, Mycobacterium Tuberculosis, and Nontuberculous Mycobacterium Peritoneal Dialysisâ€“Related Peritonitis. Kidney360, 2022, 3, 1031-1038.	0.9	4
13	Peritoneal dialysis first policy in <scp>Hong Kong</scp> for 35â€‰years: Global impact. Nephrology, 2022, 27, 787-794.	0.7	14
14	Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients. Scientific Reports, 2022, 12, .	1.6	4
15	Icodextrin in Peritoneal Dialysis: Implications on Clinical Practice and Survival Outcome. Kidney360, 2022, 3, 793-795.	0.9	0
16	Excessive risk and poor outcome of hospital-acquired peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2022, 15, 2107-2115.	1.4	3
17	Polymerase chain reaction/electrospray ionizationâ€“mass spectrometry (PCR/ESI-MS) is not suitable for rapid bacterial identification in peritoneal dialysis effluent. Peritoneal Dialysis International, 2021, 41, 96-100.	1.1	3
18	Kidney Health for Everyone Everywhere â€“ From Prevention to Detection and Equitable Access to Care. Blood Purification, 2021, 50, 1-8.	0.9	12

#	Article	IF	Citations
19	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Kidney International, 2021, 99, 278-284.	2.6	36
20	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. Indian Journal of Nephrology, 2021, 31, 83.	0.2	0
21	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. Nephron, 2021, 145, 205-211.	0.9	3
22	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. American Journal of Nephrology, 2021, 52, 1-7.	1.4	3
23	Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlledÂtrial. CKJ: Clinical Kidney Journal, 2021, 14, 991-997.	1.4	9
24	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Brazilian Journal of Medical and Biological Research, 2021, 54, e11098.	0.7	1
25	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812199527.	0.6	3
26	Living well with kidney disease by patient and careâ€partner empowerment: Kidney health for everyone everywhere. Nephrology, 2021, 26, 211-216.	0.7	0
27	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. American Journal of Hypertension, 2021, 34, 220-225.	1.0	3
28	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Nephrology (Saint-Petersburg), 2021, 25, 9-17.	0.1	0
29	Living well with kidney disease by patient and careâ€partner empowerment: kidney health for everyone everywhere. Internal Medicine Journal, 2021, 51, 163-168.	0.5	0
30	Living well with kidney disease by patient and careâ€partner empowerment: Kidney health for everyone everywhere. Journal of Renal Care, 2021, 47, 3-8.	0.6	1
31	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. CKJ: Clinical Kidney Journal, 2021, 14, 476-481.	1.4	0
32	Living Well With Kidney Disease by Patient and Care Partner Empowerment: Kidney Health for Everyone Everywhere. Kidney International Reports, 2021, 6, 553-556.	0.4	0
33	Living Well with Kidney Disease by patient and care-partner empowerment: Kidney Health for Everyone Everywhere. Journal of Nephrology, 2021, 34, 381-388.	0.9	2
34	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. Nefrologia, 2021, 41, 95-101.	0.2	2
35	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. Transplant International, 2021, 34, 391-397.	0.8	5
36	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Clinical and Experimental Nephrology, 2021, 25, 567-573.	0.7	2

#	Article	IF	Citations
37	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. Kidney Medicine, 2021, 3, 153-158.	1.0	1
38	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. Nefrologia, 2021, 41, 95-101.	0.2	2
39	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 142-149.	0.4	1
40	World Kidney Day 2021: Living Well With Kidney Disease by Patient and Care Partner Empowermentâ€"Kidney Health for Everyone Everywhere. American Journal of Kidney Diseases, 2021, 77, 474-477.	2.1	4
41	Living Well With Kidney Disease by Patient and Carepartner Empowerment: Kidney Health for Everyone Everywhere. , 2021, 31, 233-238.		3
42	Progression in Physical Frailty in Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2021, 46, 342-351.	0.9	10
43	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. Kidney Diseases (Basel, Switzerland), 2021, 7, 1-7.	1.2	2
44	Depression in dialysis. Current Opinion in Nephrology and Hypertension, 2021, 30, 600-612.	1.0	19
45	Impact of frailty and its inter-relationship with lean tissue wasting and malnutrition on kidney transplant waitlist candidacy and delisting. Clinical Nutrition, 2021, 40, 5620-5629.	2.3	11
46	Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy. Kidney Medicine, 2021, 3, 76-82.e1.	1.0	4
47	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. Nephrology Dialysis Transplantation, 2021, 36, 197-201.	0.4	1
48	Tackling Dialysis Burden around the World: A Global Challenge. Kidney Diseases (Basel, Switzerland), 2021, 7, 167-175.	1.2	17
49	Living Well With Kidney Disease by Patient and Care Partner Empowerment: Kidney Health for Everyone Everywhere. , 2021, 31, 554-559.		3
50	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2021, 32, 289.	0.4	0
51	Living Well with Kidney Disease by Patient and Care- Partner Empowerment: Kidney Health for Everyone Everywhere. Iranian Journal of Kidney Diseases, 2021, 1, 74-81.	0.1	0
52	Depression does not predict clinical outcome of Chinese peritoneal Dialysis patients after adjusting for the degree of frailty. BMC Nephrology, 2020, 21, 329.	0.8	9
53	Foreign Perspective on Achieving a Successful Peritoneal Dialysis-First Program. Kidney360, 2020, 1, 680-684.	0.9	8
54	Kidney Health for Everyone Everywhere â€“ From Prevention to Detection and Equitable Access to Care. Kidney Diseases (Basel, Switzerland), 2020, 6, 136-143.	1.2	2

#	Article	IF	Citations
55	Kidney Health for Everyone Everywhere â€“ From Prevention to Detection and Equitable Access to Care. American Journal of Nephrology, 2020, 51, 255-262.	1.4	2
56	Kidney Health for Everyone Everywhereâ€”From Prevention to Detection and Equitable Access to Care. Kidney International Reports, 2020, 5, 245-251.	0.4	1
57	Kidney Health for Everyone, Everywhereâ€”from prevention to detection and equitable access to care. Nephrology Dialysis Transplantation, 2020, 35, 367-374.	0.4	3
58	Kidney health for everyone everywhere - from prevention to detection and equitable access to care. Archivos Argentinos De Pediatria, 2020, 118, e148.	0.3	1
59	Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to Care. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812091056.	0.6	3
60	Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to Care. American Journal of Hypertension, 2020, 33, 282-289.	1.0	5
61	Kidney Health for Everyone Everywhere â€“ From Prevention to Detection and Equitable Access to Care. Nephron, 2020, 144, 162-169.	0.9	0
62	Reprint of: Kidney health for everyone everywhereâ€”from prevention to detection and equitable access to care. Nephrologie Et Therapeutique, 2020, 16, 211-216.	0.2	0
63	Kidney Health for Everyone Everywhere â€“ From prevention to detection and equitable access to care. Nefrologia, 2020, 40, 133-141.	0.2	1
64	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.4	14
65	Kidney health for everyone everywhereâ€”from prevention to detection and equitable access to care. Pediatric Nephrology, 2020, 35, 1801-1810.	0.9	4
66	Kidney health for everyone everywhereâ€”From prevention to detection and equitable access to care. Nephrology, 2020, 25, 195-201.	0.7	0
67	Helper-assisted continuous ambulatory peritoneal dialysis: Does the choice of helper matter?. Peritoneal Dialysis International, 2020, 40, 34-40.	1.1	13
68	Kidney Health for Everyone Everywhereâ€”From Prevention to Detection and Equitable Access to Care. Kidney Medicine, 2020, 2, 5-11.	1.0	2
69	Kidney Health for Everyone Everywhere â€“ From prevention to detection and equitable access to care. Nefrologia, 2020, 40, 133-141.	0.2	5
70	Kidney Health for Everyone Everywhereâ€”From Prevention to Detection and Equitable Access to Care. Journal of Renal Care, 2020, 46, 4-12.	0.6	8
71	Kidney health for everyone everywhereâ€”from prevention to detection and equitable access to care. Kidney International, 2020, 97, 226-232.	2.6	80
72	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Diseases, 2020, 75, 404-412.	2.1	92

#	Article	IF	Citations
73	Strategies to prevent kidney disease and its progression. Nature Reviews Nephrology, 2020, 16, 129-130.	4.1	54
74	Kidney health for everyone everywhere: from prevention to detection and equitable access to care. Journal of Nephrology, 2020, 33, 201-210.	0.9	5
75	Longitudinal Changes of NF-Î²B Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients. Scientific Reports, 2020, 10, 6440.	1.6	8
76	Lessons of the month 3: Duodenal perforation after polystyrene sulfonate. Clinical Medicine, 2020, 20, 107-109.	0.8	10
77	Kidney health for everyone everywhere - From prevention to detection and equitable access to care. Indian Journal of Nephrology, 2020, 30, 63.	0.2	1
78	Kidney health for everyone everywhere - from prevention to detection and equitable access to care. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2020, 31, 298.	0.4	0
79	Kidney health for everyone everywhere â€“ from prevention to detection and equitable access to care. Brazilian Journal of Medical and Biological Research, 2020, 53, e9614.	0.7	6
80	Kidney Health for Everyone Everywhere, from Prevention to Detection and Equitable Access to Care. Iranian Journal of Kidney Diseases, 2020, 14, 69-80.	0.1	1
81	Metabolomic Changes of Human Proximal Tubular Cell Line in High Glucose Environment. Scientific Reports, 2019, 9, 16617.	1.6	14
82	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology: JASN, 2019, 30, 1735-1745.	3.0	163
83	Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2019, 44, 1259-1270.	0.9	18
84	Peritoneal Dialysisâ€“Associated Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1100-1105.	2.2	80
85	Clinical practice guidelines for the provision of renal service in Hong Kong: Peritoneal Dialysis. Nephrology, 2019, 24, 27-40.	0.7	4
86	Clinical practice guidelines for the provision of renal service in Hong Kong: Accreditation of Renal Unit. Nephrology, 2019, 24, 130-132.	0.7	1
87	Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC Nephrology, 2019, 20, 77.	0.8	26
88	Peritoneal protein clearance predicts mortality in peritoneal dialysis patients. Clinical and Experimental Nephrology, 2019, 23, 551-560.	0.7	20
89	Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1601-1608.	3.0	34
90	Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 784-788.	0.4	49

#	Article	IF	Citations
91	Urinary mitochondrial DNA level as a biomarker of tissue injury in non-diabetic chronic kidney diseases. BMC Nephrology, 2018, 19, 367.	0.8	18
92	Chronic kidney disease epidemic: How do we deal with it?. Nephrology, 2018, 23, 116-120.	0.7	67
93	Peritoneal inflammation and fibrosis in Câ€reactive protein transgenic mice undergoing peritoneal dialysis solution treatment. Nephrology, 2017, 22, 125-132.	0.7	4
94	Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. Nephrology, 2017, 22, 316-321.	0.7	19
95	Inflammation and Peritoneal Dialysis. Seminars in Nephrology, 2017, 37, 54-65.	0.6	58
96	Therapeutic drug monitoring of onceâ€daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient. Nephrology, 2017, 22, 184-184.	0.7	0
97	Current Challenges and Opportunities in PD. Seminars in Nephrology, 2017, 37, 2-9.	0.6	10
98	ISPD Catheter-Related Infection Recommendations: 2017 Update. Peritoneal Dialysis International, 2017, 37, 141-154.	1.1	239
99	Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clinica Chimica Acta, 2017, 464, 106-112.	0.5	11
100	Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology, 2017, 13, 90-103.	4.1	384
101	In Memoriam of Henry Tenckhoff. Artificial Organs, 2017, 41, 697-699.	1.0	2
102	Urinary Mitochondrial DNA Level as a Biomarker of Acute Kidney Injury Severity. Kidney Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	17
103	Addressing the burden of dialysis around the world: <scp>A</scp> summary of the roundtable discussion on dialysis economics at the <scp>F</scp>irst <scp>I</scp>nternational <scp>C</scp>ongress of <scp>C</scp>hinese <scp>N</scp>ephrologists 2015. Nephrology, 2017, 22, 3-8.	0.7	10
104	Global impact of nephropathies. Nephrology, 2017, 22, 9-13.	0.7	16
105	Relatives in silent kidney disease screening (<scp>RISKS</scp>) study: <scp>A C</scp>hinese cohort study. Nephrology, 2017, 22, 35-42.	0.7	25
106	Urinary sediment mRNA level of extracellular matrix molecules in adult nephrotic syndrome. Clinica Chimica Acta, 2016, 456, 157-162.	0.5	7
107	Depression in dialysis patients. Nephrology, 2016, 21, 639-646.	0.7	104
108	Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2016, 9, 616-623.	1.4	14

#	Article	IF	Citations
109	Dialysate bacterial endotoxin as a prognostic indicator of peritoneal dialysis related peritonitis. Nephrology, 2016, 21, 1069-1072.	0.7	9
110	Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1219-1226.	2.2	15
111	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Peritoneal Dialysis International, 2016, 36, 481-508.	1.1	745
112	Treatment of hepatitis C virus infection in patients with CKD. Nature Reviews Nephrology, 2016, 12, 5-6.	4.1	4
113	Peritoneal Dialysis in Asia. Kidney Diseases (Basel, Switzerland), 2015, 1, 147-156.	1.2	36
114	Urinary mRNA levels of ELRâ€negative CXC chemokine ligand and extracellular matrix in diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 2015, 31, 699-706.	1.7	17
115	Predictors of Residual Renal Function Decline in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 180-188.	1.1	65
116	Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients. Therapeutics and Clinical Risk Management, 2015, 11, 829.	0.9	4
117	Sustainability of the Peritoneal Dialysis-First Policy in Hong Kong. Blood Purification, 2015, 40, 320-325.	0.9	40
118	Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients. PLoS ONE, 2015, 10, e0125162.	1.1	31
119	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. Journal of Rheumatology, 2015, 42, 1150-1155.	1.0	14
120	Questioning the effect of Î²-blockers on vascular stiffness. Nature Reviews Nephrology, 2015, 11, 447-448.	4.1	1
121	Long-term Outcome of Biopsy-Proven Minimal Change Nephropathy in Chinese Adults. American Journal of Kidney Diseases, 2015, 65, 710-718.	2.1	35
122	Bioimpedance Spectroscopy for the Detection of Fluid Overload in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2014, 34, 409-416.	1.1	60
123	Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1438-1443.	0.4	24
124	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. BMC Family Practice, 2014, 15, 8.	2.9	35
125	Peritonealâ€dialysis related peritonitis caused by <scp>G</scp>ordonia species: Report of four cases and literature review. Nephrology, 2014, 19, 379-383.	0.7	17
126	Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 507-512.	1.4	26

#	Article	IF	Citations
127	Antibiotic therapy during CRRTâ€"getting the dose just right. Nature Reviews Nephrology, 2014, 10, 486-488.	4.1	2
128	MicroRNAs in IgA nephropathy. Nature Reviews Nephrology, 2014, 10, 249-256.	4.1	71
129	Peritoneal Dialysisâ€"First Policy Made Successful: Perspectives and Actions. American Journal of Kidney Diseases, 2013, 62, 993-1005.	2.1	105
130	Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor. American Journal of Medicine, 2013, 126, 162-168.	0.6	24
131	Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1935-1941.	2.2	31
132	Campylobacter Peritonitis Complicating Peritoneal Dialysis: A Review of 12 Consecutive Cases. Peritoneal Dialysis International, 2013, 33, 189-194.	1.1	4
133	Acute kidney injuryâ€"global health alert. Nature Reviews Nephrology, 2013, 9, 133-135.	4.1	9
134	Infectious complications in dialysisâ€"epidemiology and outcomes. Nature Reviews Nephrology, 2012, 8, 77-88.	4.1	69
135	Cross sectional survey on the concerns and anxiety of patients waiting for organ transplants. Nephrology, 2012, 17, 514-518.	0.7	18
136	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology, 2011, 16, 53-56.	0.7	20
137	Asian Chronic Kidney Disease (CKD) Best Practice Recommendations - Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). Nephrology, 2011, 16, no-no.	0.7	50
138	Increasing homeâ€based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Hemodialysis International, 2011, 15, 10-14.	0.4	11
139	Repeat Peritonitis in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 827-833.	2.2	30
140	Elevated Levels of miR-146a and miR-155 in Kidney Biopsy and Urine from Patients with IgA Nephropathy. Disease Markers, 2011, 30, 171-179.	0.6	109
141	Expression of MicroRNAs in the Urinary Sediment of Patients with IgA Nephropathy. Disease Markers, 2010, 28, 79-86.	0.6	93
142	Effect of Membrane Permeability on Inflammation and Arterial Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 652-658.	2.2	23
143	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Peritoneal Dialysis International, 2010, 30, 393-423.	1.1	770
144	The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism. CKJ: Clinical Kidney Journal, 2009, 2, 205-212.	1.4	6

#	Article	IF	Citations
145	Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment. American Journal of Kidney Diseases, 2009, 54, 702-710.	2.1	62
146	Peritoneal Dialysis Patient Selection: Characteristics for Success. Advances in Chronic Kidney Disease, 2009, 16, 160-168.	0.6	26
147	Treatment of metabolic syndrome in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29 Suppl 2, S149-52.	1.1	15
148	Success of the peritoneal dialysis programme in Hong Kong. Nephrology Dialysis Transplantation, 2008, 23, 1475-1478.	0.4	100
149	Metabolic syndrome in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2008, 1, 206-214.	1.4	10
150	Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 91-97.	2.2	57
151	StaphylococcusaureusPeritonitis Complicates Peritoneal Dialysis: Review of 245 Consecutive Cases. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 245-251.	2.2	94
152	Continuous Ambulatory Peritoneal Dialysis Peritonitis: Broth Inoculation Culture versus Water Lysis Method. Nephron Clinical Practice, 2007, 105, c121-c125.	2.3	23
153	Development of the â€œPeritoneal Dialysis Firstâ€•Model in Hong Kong. Peritoneal Dialysis International, 2007, 27, 53-55.	1.1	74
154	Increased Utilization of Peritoneal Dialysis to Cope with Mounting Demand for Renal Replacement Therapyâ€”Perspectives from Asian Countries. Peritoneal Dialysis International, 2007, 27, 59-61.	1.1	25
155	Continuous Ambulatory Peritoneal Dialysis is Better than Automated Peritoneal Dialysis as First-Line Treatment in Renal Replacement Therapy. Peritoneal Dialysis International, 2007, 27, 153-157.	1.1	24
156	Maximizing the success of peritoneal dialysis in high transporters. Peritoneal Dialysis International, 2007, 27 Suppl 2, S148-52.	1.1	4
157	Continuous ambulatory peritoneal dialysis is better than automated peritoneal dialysis as first-line treatment in renal replacement therapy. Peritoneal Dialysis International, 2007, 27 Suppl 2, S153-7.	1.1	3
158	Good patient and technique survival in elderly patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International, 2007, 27 Suppl 2, S196-201.	1.1	25
159	Increased utilization of peritoneal dialysis to cope with mounting demand for renal replacement therapy--perspectives from Asian countries. Peritoneal Dialysis International, 2007, 27 Suppl 2, S59-61.	1.1	7
160	Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Kidney Diseases, 2006, 47, 751-760.	2.1	177
161	Predictive Value of Dialysate Cell Counts in Peritonitis Complicating Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 768-773.	2.2	78
162	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International, 2005, 67, S2-S7.	2.6	55

#	Article	IF	Citations
163	Prevalence of silent kidney disease in Hong Kong: The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney International, 2005, 67, S36-S40.	2.6	44
164	Hypokalemia in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Implication. American Journal of Kidney Diseases, 2005, 46, 128-135.	2.1	84
165	Peritoneal Albumin Excretion is a Strong Predictor of Cardiovascular Events in Peritoneal Dialysis Patients: A Prospective Cohort Study. Peritoneal Dialysis International, 2005, 25, 445-452.	1.1	46
166	Transforming Growth Factor-Î²1 Gene Polymorphism in Renal Transplant Recipients. Renal Failure, 2005, 27, 671-675.	0.8	21
167	The clinical course of peritoneal dialysis-related peritonitis caused by Corynebacterium species. Nephrology Dialysis Transplantation, 2005, 20, 2793-2796.	0.4	27
168	The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Peritoneal Dialysis International, 2005, 25 Suppl 3, S80-3.	1.1	12
169	Cefazolin plus Ceftazidime versus Imipenem / Cilastatin Monotherapy for Treatment of Capd Peritonitis â€" a Randomized Controlled Trial. Peritoneal Dialysis International, 2004, 24, 440-446.	1.1	37
170	The clinical course of culture-negative peritonitis complicating peritoneal dialysis. American Journal of Kidney Diseases, 2003, 42, 567-574.	2.1	73
171	Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis. Annals of Internal Medicine, 2003, 139, 105.	2.0	252
172	Is There a Survival Advantage in Asian Peritoneal Dialysis Patients?. International Journal of Artificial Organs, 2003, 26, 363-372.	0.7	12
173	Conservative management of polymicrobial peritonitis complicating peritoneal dialysisâ€"a series of 140 consecutive cases. American Journal of Medicine, 2002, 113, 728-733.	0.6	56
174	Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: A prospective, randomized, controlled, multicenter study. American Journal of Kidney Diseases, 2002, 40, 373-380.	2.1	70
175	Feasibility of Resuming Peritoneal Dialysis after Severe Peritonitis and Tenckhoff Catheter Removal. Journal of the American Society of Nephrology: JASN, 2002, 13, 1040-1045.	3.0	101
176	Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases. Kidney International, 2001, 59, 2309-2315.	2.6	108
177	Independent Effects of Residual Renal Function and Dialysis Adequacy on Actual Dietary Protein, Calorie, and Other Nutrient Intake in Patients on Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2450-2457.	3.0	122
178	Impact of Dialysis Adequacy on the Mortality and Morbidity of Anuric Chinese Patients Receiving Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 355-360.	3.0	93
179	Noncardiogenic Pulmonary Edema Associated with Triazolam. Journal of Toxicology: Clinical Toxicology, 1995, 33, 185-187.	1.5	2
180	Salt and Water Balance in Peritoneal Dialysis. , 0, , 488-499.		1

#	Article	IF	Citations
181	Reply to â€˜Stability and compatibility of antibiotics in PD solutions - Call for including antibiotics for drug-resistant infectionsâ€™. CKJ: Clinical Kidney Journal, 0, , .	1.4	0